BlackRock
COLL icon

BlackRock’s Collegium Pharmaceutical COLL Stock Holding History

BlackRock’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197M Buy
5,441,202
+307,175
+6% +$10.5M ﹤0.01% 1806
2026
Q1 		$170M Buy
5,134,027
+34,325
+0.7% +$1.45M ﹤0.01% 1769
2025
Q4 		$236M Sell
5,099,702
-78,342
-2% -$3.28M ﹤0.01% 1572
2025
Q3 		$181M Sell
5,178,044
-163,812
-3% -$5.69M ﹤0.01% 1724
2025
Q2 		$158M Sell
5,341,856
-112,402
-2% -$3.21M ﹤0.01% 1758
2025
Q1 		$163M Sell
5,454,258
-101,333
-2% -$3.1M ﹤0.01% 1711
2024
Q4 		$159M Buy
5,555,591
+35,784
+0.6% +$1.18M ﹤0.01% 1793
2024
Q3 		$213M Sell
5,519,807
-273,576
-5% -$9.76M ﹤0.01% 1620
2024
Q2 		$187M Sell
5,793,383
-72,516
-1% -$2.51M ﹤0.01% 1654
2024
Q1 		$228M Buy
5,865,899
+78,906
+1% +$2.76M 0.01% 1562
2023
Q4 		$178M Sell
5,786,993
-453,971
-7% -$11.4M ﹤0.01% 1723
2023
Q3 		$139M Buy
6,240,964
+162,645
+3% +$3.71M ﹤0.01% 1787
2023
Q2 		$131M Buy
6,078,319
+266,330
+5% +$6.05M ﹤0.01% 1867
2023
Q1 		$139M Buy
5,811,989
+79,724
+1% +$2.11M ﹤0.01% 1805
2022
Q4 		$133M Sell
5,732,265
-10,865
-0.2% -$219K ﹤0.01% 1817
2022
Q3 		$92M Buy
5,743,130
+92,014
+2% +$1.62M ﹤0.01% 2019
2022
Q2 		$100M Sell
5,651,116
-66,189
-1% -$1.11M ﹤0.01% 2002
2022
Q1 		$116M Buy
5,717,305
+85,645
+2% +$1.62M ﹤0.01% 2040
2021
Q4 		$105M Buy
5,631,660
+4,352
+0.1% +$84.8K ﹤0.01% 2187
2021
Q3 		$111M Sell
5,627,308
-39,319
-0.7% -$850K ﹤0.01% 2148
2021
Q2 		$134M Sell
5,666,627
-219,909
-4% -$5.08M ﹤0.01% 2073
2021
Q1 		$140M Buy
5,886,536
+3,048,319
+107% +$72.4M ﹤0.01% 1981
2020
Q4 		$56.9M Buy
2,838,217
+29,533
+1% +$577K ﹤0.01% 2393
2020
Q3 		$58.5M Sell
2,808,684
-7,511
-0.3% -$136K ﹤0.01% 2199
2020
Q2 		$49.3M Buy
2,816,195
+318,769
+13% +$6.24M ﹤0.01% 2260
2020
Q1 		$40.8M Sell
2,497,426
-68,501
-3% -$1.41M ﹤0.01% 2183
2019
Q4 		$52.8M Buy
2,565,927
+6,309
+0.2% +$105K ﹤0.01% 2329
2019
Q3 		$29.4M Buy
2,559,618
+71,139
+3% +$812K ﹤0.01% 2595
2019
Q2 		$32.7M Buy
2,488,479
+165,018
+7% +$2.21M ﹤0.01% 2565
2019
Q1 		$35.2M Sell
2,323,461
-296,257
-11% -$4.74M ﹤0.01% 2481
2018
Q4 		$45M Buy
2,619,718
+210,145
+9% +$3.6M ﹤0.01% 2306
2018
Q3 		$35.5M Buy
2,409,573
+157,300
+7% +$2.79M ﹤0.01% 2567
2018
Q2 		$53.7M Buy
2,252,273
+272,302
+14% +$6.7M ﹤0.01% 2318
2018
Q1 		$50.6M Buy
1,979,971
+14,405
+0.7% +$343K ﹤0.01% 2259
2017
Q4 		$36.3M Buy
1,965,566
+79,466
+4% +$1.14M ﹤0.01% 2464
2017
Q3 		$19.8M Buy
1,886,100
+34,773
+2% +$383K ﹤0.01% 2816
2017
Q2 		$23.2M Buy
1,851,327
+370,120
+25% +$3.66M ﹤0.01% 2708
2017
Q1 		$14.9M Buy
1,481,207
+1,480,639
+260,676% +$22M ﹤0.01% 2923
2016
Q4 		$9K Hold
568
– – ﹤0.01% 3410
2016
Q3 		$11K Hold
568
– – ﹤0.01% 3383
2016
Q2 		$7K Sell
568
-181
-24% -$2.99K ﹤0.01% 3457
2016
Q1 		$14K Buy
+749
New +$13.6K ﹤0.01% 3009

Other funds holding COLL

JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock's COLL Position: Q2 2026 in Review

BlackRock increased its Collegium Pharmaceutical (COLL) stake by 6% in Q2 2026, buying an estimated $10.5M and bringing the position to 5,441,202 shares worth $197M. The position accounts for ﹤0.01% of the portfolio, ranked #1806.

BlackRock first reported a position in COLL in Q1 2016 and has held it in 42 quarters since. The position peaked at $236M in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • BlackRock held 5,441,202 shares of Collegium Pharmaceutical worth $197M as of Q2 2026.
  • BlackRock bought 307,175 Collegium Pharmaceutical shares in Q2 2026, an estimated $10.5M.
  • Collegium Pharmaceutical made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1806 holding.
  • BlackRock first reported a position in Collegium Pharmaceutical in Q1 2016 and has held it in 42 quarters since.
  • BlackRock's Collegium Pharmaceutical position peaked at $236M in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.